HUTCHMED (China) Limited (HKG:0013)

Market Cap	18.99B -5.8%
Revenue (ttm)	4.31B -8.8%
Net Income	140.24M -96.2%
EPS	0.16 -96.2%
Shares Out	n/a
PE Ratio	137.27
Forward PE	37.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,000
Open	21.60
Previous Close	21.68
Day's Range	21.60 - 21.96
52-Week Range	15.57 - 25.58
Beta	0.36
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,790
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0013

Financial Performance

In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error